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Overview of Therapeutic Ultrasound 
Applications and Safety Considerations
ltrasound has seen development not only as a diagnostic
imaging modality but also as a therapeutic modality in
which energy is deposited in tissue to induce various bio-
logical effects. Medical uses of ultrasound for therapy began to be ex-
plored in the 1930s. Early applications were tried for various
conditions using the mechanism of tissue heating.1 Over the fol-
lowing decades, scientific advances allowed improved methods for
effective treatment of Meniere disease by destruction of the vestibu-
lar nerve and Parkinson disease using focused ultrasound for local-
ized tissue destruction in the brain.2,3 By the 1970s, the use of
therapeutic ultrasound was established for physiotherapy, and re-
search continued on more difficult applications in neurosurgery4
and for cancer treatment.5 Subsequently, the development of ther-
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REVIEW ARTICLE
Applications of ultrasound in medicine for therapeutic purposes have been accepted
and beneficial uses of ultrasonic biological effects for many years. Low-power ultra-
sound of about 1 MHz has been widely applied since the 1950s for physical therapy in
conditions such as tendinitis and bursitis. In the 1980s, high-pressure-amplitude shock
waves came into use for mechanically resolving kidney stones, and “lithotripsy” rapidly
replaced surgery as the most frequent treatment choice. The use of ultrasonic energy for
therapy continues to expand, and approved applications now include uterine fibroid
ablation, cataract removal (phacoemulsification), surgical tissue cutting and hemosta-
sis, transdermal drug delivery, and bone fracture healing, among others. Undesirable
bioeffects can occur, including burns from thermal-based therapies and severe hemor-
rhage from mechanical-based therapies (eg, lithotripsy). In all of these therapeutic ap-
plications of ultrasound bioeffects, standardization, ultrasound dosimetry, benefits
assurance, and side-effect risk minimization must be carefully considered to ensure an
optimal benefit to risk ratio for the patient. Therapeutic ultrasound typically has well-
defined benefits and risks and therefore presents a manageable safety problem to the
clinician. However, safety information can be scattered, confusing, or subject to com-
mercial conflicts of interest. Of paramount importance for managing this problem is
the communication of practical safety information by authoritative groups, such as the
American Institute of Ultrasound in Medicine, to the medical ultrasound community.
In this overview, the Bioeffects Committee of the American Institute of Ultrasound in
Medicine outlines the wide range of therapeutic ultrasound methods, which are in clin-
ical use or under study, and provides general guidance for ensuring therapeutic ultra-
sound safety.
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apeutic ultrasound has accelerated, with a wide range of
methods now in use. The potent application of ultrasound
for therapeutic efficacy also carries the risk of unintentional
adverse bioeffects, which can lead to severe, even life-
threatening patient injury. Therefore, standardization, ul-
trasound dosimetry, benefits assurance, and side-effect risk
minimization must be carefully considered to ensure an
optimal outcome for the patient.
The purpose of this review is to briefly outline the re-
cent development of therapeutic ultrasound applications
and specialized devices, which have been approved for use,
together with associated safety considerations. Therapeutic
applications of ultrasound may be used clinically after gov-
ernment approval (eg, by the Food and Drug Administra-
tion [FDA] in the United States) for marketing suitable
treatment devices. A list of therapy applications with FDA-
approved devices in clinical use is provided in Table 1. The
fundamental basis behind the ultrasound-mediated depo-
sition of energy and mechanisms for biological effects are
discussed, followed by a discussion of ultrasound treat-
ment methods using heating, which include physical
therapy, hyperthermia, and high-intensity focused ul-
trasound (HIFU). Nonthermal applications are then re-
viewed, including extracorporeal shock wave lithotripsy
(ESWL), intracorporeal lithotripsy, and lower-power,
kilohertz- frequency ultrasound devices. Some ultrasound
therapy methods have uncertain, possibly multiple mech-
anisms, including skin permeabilization for drug delivery
and low-intensity pulsed ultrasound, which can accelerate
the healing of bone fractures. Prospective new methods of
therapeutic ultrasound are mentioned at the end, including
new microbubble- or cavitation-based treatment methods.
Last, the reader is reminded of important safety consider-
ations, and general guidelines are presented. There is no
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Table 1. Food and Drug Administration—Approved Modes for Ultrasound Therapy
Therapy Therapeutic Bioeffect Device Characteristics General
Method Outcome Mechanism Applicator Frequency Delivery Reference
Unfocused beam Tissue warming Heating Portable handheld 1–3 MHz Continuous or Robertson and 
repeated bursts Baker6
Hyperthermia Cancer therapy Regional heating Multielement applicator 1–3.4 MHz 1 h Samulski et al7
High-intensity Uterine fibroid Thermal lesion Computer directed 0.5–2 MHz Long  bursts Tempany et al8
focused ultrasound ablation
High-intensity 
focused ultrasound Glaucoma relief Permeabilization Fixed probe with water 4.6 MHz 1–3 s Burgess et al9
bath
High-intensity Laparoscopic tissue Thermal lesion Handheld 4 MHz Long bursts Klingler et al10
focused ultrasound ablation
High-intensity Laparoscopic or Thermal lesion Handheld 3.8–6.4 MHz Long bursts Ninet et al11
focused ultrasound open surgery
Focused ultrasound Skin tissue tightening Thermal lesion Handheld, imaging 4.4–7.5 MHz 20-to 50-ms Alam et al12
and treatment bursts
Extracorporeal Kidney stone Mechanical stress, Mainframe with ≈150 kHz Shock waves Weizer et al13
lithotripsy comminution cavitation image guidance
Intracorporeal Kidney stone Mechanical stress, Percutaneous 25 kHz Continuous Lowe and
lithotripsy comminution cavitation probes Knudsen14
Extracorporeal Plantar fasciitis, Unknown Mainframe with ≈150 kHz Shock waves Haake et al15
shock wave therapy epicondylitis applicator head
Phacoemulsification Lens removal Vibration, Generator with probe 40 kHz Continuous Packer et al16
cavitation
Ultrasound-assisted Adipose tissue Fat liquefaction, Generator with probe 20–30 kHz Continuous Mann et al17
liposuction removal cavitation
Tissue cutting and Laparoscopic or Thermal lesion, Handheld 55.5 kHz Continuous Koch et al18
vessel sealing open surgery vibration
Intravascular Thrombus dissolution Unknown, gas Intravascular catheter 2.2 MHz Continuous Parikh et al19
ultrasound body activation
Skin perm- Transdermal drug Unknown Handheld 55 kHz Continuous Smith20
eabilization delivery
Low-intensity pulsed Bone fracture healing Unknown Attached transducer 1.5 MHz Pulsed, long Gebauer et al21
ultrasound duration
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doubt that continued biophysical discoveries in ultrasound
will lead to new treatments and applications. As therapeu-
tic ultrasound’s renaissance continues, new treatments al-
ready well established in the laboratory will be translated in
the near future to the clinic.
The Biophysical Bases for Therapeutic 
Ultrasound Applications
Ultrasonic energy can be a potent modality for generating
biological effects. Given sufficient knowledge of the etiol-
ogy and exposimetry, bioeffects can be planned for thera-
peutic purposes or avoided in diagnostic applications. For
therapy, ultrasound can induce effects not only through
heating but also through nonthermal mechanisms, includ-
ing ultrasonic cavitation, gas body activation, mechanical
stress, and other undetermined nonthermal processes.22
Starting from the diagnostic reference frame, ultra-
sound is usually produced from a piezoceramic crystal in
very short, ie, 1- to 5-cycle, pulses. Diagnostic ultrasound is
often characterized by the center frequency of the pulses
(typically in the 2- to 12-MHz range), which is usually a
frequency inherent to the thickness of the ceramic crystal.
As the pressure amplitude, the frequency, or the propaga-
tion length is increased, the ultrasound wave can distort,
which could ultimately lead to a discontinuity or shock in
the waveform. With regard to bioeffects, increasing the fre-
quency, nonlinear acoustic distortion, or pulse length can
increase heating and enhance some nonthermal mecha-
nisms, eg, radiation force. Decreasing the frequency in-
creases the likelihood of cavitation and gas body activation.
Increasing the power or intensity tends to increase the
likelihood and magnitude of all bioeffects mechanisms.
Therapeutic ultrasound devices may use short bursts or
continuous waves to deliver effective ultrasonic energy to
tissues. Some devices operate at higher amplitudes and
therefore tend to produce shocked or distorted waves.
Ultrasound-induced heating is the result of the ab-
sorption of ultrasonic energy in biological tissue. For diag-
nostic ultrasound, temperature elevations and the potential
for bioeffects are kept relatively low or negligible23 by care-
fully described indications for use, applying the ALARA
(as low as reasonably achievable) principal, limited tem-
poral average intensities, and generally short exposure du-
rations. Therapeutic applications of ultrasonic heating
therefore either use longer durations of heating with unfo-
cused beams or use higher-intensity (than diagnostic) 
focused ultrasound. The use of unfocused heating, for ex-
ample, in physical therapy to treat highly absorbing tissues
such as bone or tendon, can be moderated to produce en-
hanced healing without injury. Alternatively, the heat can
be concentrated by focused beams until tissue is coagu-
lated for the purpose of tissue ablation. Ultrasonic heating,
which can lead to irreversible tissue changes, follows an in-
verse time-temperature relationship. Depending on the
temperature gradients, the effects from ultrasound expo-
sure can include mild heating, coagulative or liquefactive
necrosis, tissue vaporization, or all three.
Ultrasonic cavitation and gas body activation are
closely related mechanisms, which depend on the rarefac-
tional pressure amplitude of ultrasound waves. Ultrasound
transmitted into a tissue may have rarefactional pressure
amplitudes of several megapascals. This tensile stress is
supported by the medium, and, for example, a 2-MPa rar-
efactional pressure, which is common even for diagnostic
ultrasound, represents a negative tension 20 times the at-
mospheric pressure (ie, 0.1 MPa). This high rarefactional
pressure can act to initiate cavitation activity in tissue when
suitable cavitation nuclei are present or directly induce pul-
sation of preexisting gas bodies, such as occur in lung and
intestine or with ultrasound contrast agents. Cavitation
and gas body activation primarily cause local tissue injury
in the immediate vicinity of the cavitational activity, in-
cluding cell death and hemorrhage of blood vessels.
Other potential mechanisms for biological effects of
ultrasound include the direct action of the compressional,
tensile, and shear stresses. In addition, second-order phe-
nomena, which depend on transmitted ultrasonic energy,
include radiation pressure, forces on particles, and acoustic
streaming. For high-power or high-amplitude ultrasound
for therapy, several different mechanisms may be con-
tributing concurrently to the total biological impact of the
treatment. In addition to direct physical mechanisms for bio-
effects, there are secondary physical, biological, and physio-
logic mechanisms that cause further impact on the organism.
Some examples are vasoconstriction, ischemia, extravasa-
tion, reperfusion injury, and immune responses.24–26 Some-
times these secondary effects are greater than the direct
insult from the ultrasound.
Therapeutic Applications of Ultrasound
Based on Heating
Physical Therapy
Unfocused beams of ultrasound for physical therapy were
the first clinical application, dating to the 1950s, which
often has been referred to simply as “therapeutic ultra-
sound.”6 This modality now typically has a base unit for
generating an electrical signal and a handheld transducer.
The handheld transducer is applied with coupling gel and
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moved in a circular motion over an injured or painful area
of the anatomy to treat conditions such as bursitis of the
shoulder and tendonitis by trained physical therapy tech-
nicians. The objective is to warm tendons, muscle, and
other tissue to improve blood flow and accelerate healing.
The coupling medium can also include various com-
pounds for enhancing the treatment. Ultrasound applica-
tion can assist by promoting transport of the compound
into the skin, a method sometimes called sonophoresis or
phonophoresis (as opposed to electrophoresis).27 Drugs,
such as lidocaine and cortisol, have been used extensively
in sports medicine. The level of clinical benefit to the pa-
tient from physical therapy ultrasound treatments remains
uncertain.6,28,29 However, the risk of harm, such as burns,
appears to be low when the modality is properly applied.
Overall, ultrasound for physical therapy has therefore pro-
vided a modest level of efficacy and patient benefit but also
a low level of risk. 
Hyperthermia
A substantial effort during the 1980s and 1990s sought to
develop means to ultrasonically heat relatively large volumes
of tissue for the purpose of cancer therapy. This method of
hyperthermia involves uniformly heating a tumor to about
42°C to 45°C for about 30 to 60 minutes, which appears to
be effective in reducing tumor growth.30 Multielement ap-
plicators have been used at 1 to 3.4 MHz.7,31 In clinical trials,
hyperthermia was used with or without radiation therapy,
and modest efficacy has been reported.32 Research suggests
that hyperthermia may be advantageous for drug delivery
treatment using nanoparticles.33 However, the moderate-
temperature hyperthermia method has not progressed to
widespread clinical use, and the effort in hyperthermia can-
cer treatment has shifted to the use of HIFU. 
High-Intensity Focused Ultrasound
High-intensity focused ultrasound was initially studied
clinically for thermal ablation of inoperable brain tissue for
Parkinson disease.2,34 In an HIFU system, a signal genera-
tor is connected to a focusing transducer, which produces
very high local intensities of greater than 1 kW/cm2 of
0.5- to 7-MHz ultrasound at the focal spot. The lesion pro-
duced in tissue typically may be a few millimeters in diam-
eter and length. The position of this spot must be carefully
controlled and moved to ablate larger volumes of tissue.
This method is approved by the FDA in the United States
for treating uterine fibroids,8 cardiac ablation,11 visceral soft
tissue ablation,10 and aesthetic treatment to lift the eye-
brow.12,35 In addition, a method was developed and was
approved for treatment of glaucoma using HIFU.9
In addition to the devices approved by the FDA for
clinical use, there are several procedures that are being in-
vestigated for clinical application.36 High-intensity focused
ultrasound application in therapy and treatment of disease
is one of the more active areas of research and development
among all of the nonionizing energy modalities such as ra-
diofrequency, lasers, and microwaves. For example, HIFU
is under investigation for therapeutic modulation of nerve
conductance.37 Among other applications, the oldest and
possibly the most investigated area (particularly outside the
Unites States) is the treatment of benign prostatic hyper-
plasia and the treatment of prostate cancer using HIFU. 
A number of multicenter and systematic studies with sev-
eral-year follow-up have established the use of HIFU as a
viable option for the management of prostate cancer.38,39
A key element of therapeutic applications of ultra-
sonic energy is the capability to focus energy several mil-
limeters to centimeters away from the transducer plane.
It is, therefore, very important to accurately determine the
location of the treatment zone with ultrasound systems.
Furthermore, the tissue changes in the treatment zone
must be reliably monitored to confirm that adequate treat-
ment has been achieved. The focused ultrasound beam
can then be moved to a different location to complete the
treatment of the planned volume. Two methods used for
image guidance and treatment monitoring are magnetic
resonance imaging and ultrasound imaging. Magnetic res-
onance imaging can measure temperature changes dur-
ing therapy, within the treatment zone of therapeutic
ultrasound procedures.40 Specialized clinical systems have
ultrasound therapy subsystems integrated into magnetic
resonance scanners, which are used for uterine fibroid
treatment8 and brain,41,42 breast,43,44 bone,45 liver,46 and
prostate cancer management.47 Ultrasound-based guid-
ance and monitoring offer the possibility of systems that
incorporate both the treatment and imaging modality in
one compact system. Ultrasound image monitoring of
tissue changes during ultrasound therapy is still under 
development, and some of the possible methods are based
on a combination of the speed of sound, attenuation, stiff-
ness, and vapor content changes in the target region,48–
51 including boiling detection.52
In addition to external focused devices, a number of
other devices and systems are being developed for soft tis-
sue coagulation, which are primarily used in noninvasive
approaches: percutaneously for interstitial liver tissue abla-
tion53 or through natural orifices such as the transrectal ap-
proach for prostate treatments.38 For example, transurethral
ultrasound has been proposed for heating the prostate47,54;
endoscopic treatment with an intraductal ultrasound probe
Miller et al—Therapeutic Ultrasound Applications and Safety Considerations
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has been used to treat bile duct tumors55; and an intravas-
cular approach has been used for cardiac ablation.56
Considerable research and development are being
pursued in the area of noninvasive aesthetic applications.
Focused ultrasound in these applications is directed
within the first 2 to 20 mm of the skin and subcutaneous
tissue (dermis to subcutaneous fat). Very small lesions of
approximately 1 mm3 up to several tens of cubic cen-
timeters can be produced. The approach may provide a
safer alternative to liposuction for cosmetic applica-
tions.57 Superficial tissue is exposed to HIFU, leading ei-
ther to a contraction of collagen-based tissue (dermis) or
to destruction of adipose tissue.35,58 A clinical system has
been approved for fat debulking in the European Union
and Canada.59 Depending on the device, as well as the
cosmetic application, both thermal and nonthermal
mechanisms within an ultrasonic field are used for these
procedures. One of these devices is currently approved
for clinical use in the United States,12 and others are in use
worldwide. Long-term use of this technology, as well as
regulatory approval, is still evolving.
High-intensity focused ultrasound applications involve
delivery of substantial ultrasonic energy to localized areas,
and undesired tissue injury is always a consideration. Typ-
ically, unwanted burns and pain can occur. In addition,
HIFU can cause vasospasms and hemorrhage under con-
ditions that generate concomitant cavitation in tissue.60
Other substantial bioeffects and complications can also
occur, with unique risk-benefit considerations for each ap-
plication. Treatment of the prostate, such as for prostate
cancer, can lead to several urologic complications, including
impotence and incontinence,61 which can also accompany
other types of treatment for prostate cancer. High-intensity
focused ultrasound has been used to treat atrial fibrillation
by tissue ablation to produce pulmonary vein isolation.
However, severe complications can occur due to creation of
an atrial-esophageal fistula,62 a concern that is difficult to
eliminate.63 Treatment of hepatic and pancreatic cancer can
also lead to serious complications, including fistula forma-
tion and rib necrosis with delayed rib fracture.64 Detailed
safety considerations should accompany the introduction of
HIFU applications into clinical practice to ensure a benefit
while minimizing risk to the patient. 
Therapeutic Applications of Ultrasound
Based on Nonthermal Mechanisms
Extracorporeal Shock Wave Lithotripsy
Extracorporeal shock wave lithotripsy is a widely used ul-
trasound therapy, which relies on nonthermal mechanisms
for its efficacy.13,65 When introduced in the 1980s,
lithotripsy gained rapid acceptance and became the dom-
inant treatment method. Shock wave devices similar to
lithotripters are approved and marketed for orthopedic in-
dications such as plantar fasciitis and epicondylitis.15 The
use of shock waves for treating other problems, such as gall-
bladder stones, has also been explored, but none have
achieved widespread usage. Over 50 lithotripter devices
have been on the US market. Fluoroscopy is used for tar-
geting the acoustic focus on the stone in the United States,
although some lithotripters have B-mode ultrasound for
targeting. The first lithotripters were electrohydraulic,
using an underwater spark source and a reflector. Most
lithotripters now are of the electromagnetic design, which
deposits a high transient current through a coil that in turn
produces displacement of a plate. Very few lithotripters
use piezoceramic sources. All produce about the same
waveform: a 1-microsecond shocked spike of about 50
MPa followed by an approximately 10-MPa, 4-microsec-
ond negative pressure tail. The center frequency might be
estimated to be about 150 kHz, although it is not a com-
monly determined parameter. There was a trend to more
focused machines, relative to early spark gap models, but
that has fallen out of favor. Evidence has been presented
for a reduction in clinical effectiveness and safety for
highly focused shock waves65 and for the dependence of
fragmentation mechanisms on the beam width.66,67
For ESWL treatment, the source is coupled to the pa-
tient by a water pillow and transmission gel and in the re-
maining original lithotripters through a water bath.
Coupling has recently been recognized as an important fac-
tor in ESWL treatment efficacy; a point that has implica-
tions across therapeutic ultrasound.68 About 3000 shock
waves are triggered at about a 2-Hz repetition rate to pul-
verize the stone so that the pieces (<2 mm) can pass nat-
urally in urine. The prominent mechanism is the wave
running over the stone, creating shear waves to tear the
stone apart from within. Cavitation chips away from the
outside, adding cracks that grow by dynamic fatigue and
further grind down the stone to a passable size.67
Lithotripsy has several important biological side ef-
fects. It causes injury to virtually all patients.69 Blood ves-
sel walls break, and there is bleeding into the connective
tissue interstitium, which can result in bruising of the
parenchyma or the formation of massive subcapsular
hematomas. Inflammation ensues (ie, lithotripsy nephri-
tis), which can lead to scar formation70 and permanent loss
of functional renal mass.71 In addition to and likely a result
of this direct injury cascade, lithotripsy can lead to an ac-
celerated rise in systemic blood pressure, a decrease in
J Ultrasound Med 2012; 31:623–634 627
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renal function, onset of hypertension, an increase in the
rate of stone recurrence, and an exacerbation of stone dis-
ease.72,73 A single retrospective study has linked lithotripsy
and diabetes mellitus.74
The risks of these adverse bioeffects in lithotripsy have
stimulated investigation into mitigation methods with
some success.65 For example, a slower repetition rate (1
Hz) is safer and more effective than the common fast rate
(2 Hz),75 and a pause early in treatment nearly eliminates
injury in animals.13,76 Overall, lithotripsy has been a thera-
peutic ultrasound method with a high level of efficacy and
patient benefits but also some important risks, particularly
for patients requiring repeated treatments. The develop-
ment of safer treatment protocols for lithotripsy is a prime
example of the potential value of research on risk mitiga-
tion for optimizing the patient risk-benefit profile in ther-
apeutic ultrasound.
Intracorporeal Lithotripsy
Lithotripsy is also accomplished by minimally invasive
probes, which are advanced to the stone. Intracorporeal
lithotripsy is the favored treatment for many patients, for
example, for very large stones, and many different meth-
ods and techniques have been reported. The stone may be
imaged for guidance by external ultrasound imaging or flu-
oroscopy or by ureteroscopic, endoscopic, or laparoscopic
methods. Rigid probes may be manipulated percuta-
neously, but some flexible probes can be applied via the
ureter. Rigid ultrasound probes can use both pneumatic
action at a few hertz to 1000 Hz and ultrasonic action at
about 25 kHz.14,77 Electrohydraulic probes, which gener-
ate a vaporous cavity at the tip (similar to the spark gap ex-
ternal lithotripter but without focusing),78 have been used
in the past. Intracorporeal lithotripsy carries risks of hem-
orrhage, ureteral perforation, urinary tract trauma, and in-
fection due to the invasive nature of the procedures.
Kilohertz-Frequency Ultrasound Devices 
Ultrasound systems operating in the kilohertz frequency
regime (20–90 kHz), similar to “sonicators” used in bio-
logical research to break up cells and tissues, are used rou-
tinely in general and advanced surgical procedures for
tissue cutting and hemostasis as well as for tissue removal.
These systems appear to act primarily though localized
biophysical effects close to the probe tip, rather than via
radiated ultrasound waves. For example, a kilohertz-
frequency ultrasound probe is used for phacoemulsifica-
tion to remove the lens of the eye during surgery for
cataracts.16 The probe appears to mechanically chop up
the lens, possibly aided by ultrasonic cavitation, with the
lens debris removed by suction through the probe. The
procedure is well established in ophthalmology and mini-
mizes the impact on the lens capsule.
Surgical ultrasound instruments, known as “harmonic
scalpels,” have a 40- to 80-kHz vibrating titanium rod with
a static clamp member, between which the tissue (and
blood vessels) is rapidly coagulated due to localized fric-
tional heating.18 Another procedure, ultrasound-assisted
liposuction, is widely used in cosmetic surgery for the pur-
pose of removing excessive fat tissue.17 The mechanism of
action apparently involves cavitational fat cell breakup with
removal of the fat emulsion by suction through the probe.
This procedure is invasive and can lead to complications
such as bleeding, scarring, and infection.
Therapeutic Applications of Ultrasound
With Multiple Mechanisms
Catheter-Based Ultrasound
Intravascular catheters have been developed with mega-
hertz-frequency ultrasound transducers placed near the tip
for enhancing dissolution of thrombi.19 The catheter is
placed into a deep vein thrombus, and the ultrasound is di-
rected radially into the thrombus. In addition, there are pro-
visions for infusion of thrombolytic drugs, such as tissue
plasminogen activator. The ultrasound accelerates the ac-
tion of the thrombolytic drugs so that the total infusion
doses of drugs and treatment times can be reduced sub-
stantially. The role of this method and the full range of its
clinical usefulness for thrombolysis are still being evaluated.
Skin Permeabilization
For transdermal drug delivery, the stratum corneum (≈10–
30 μm in thickness) forms a barrier to passive drug diffu-
sion for molecules that have a weight of greater than 500
Da.79 One effect of low-frequency ultrasound (<100 kHz)
is its ability increase permeability of the stratum corneum,
which is considered a primary barrier to protein diffu-
sion.80,81 The treatment can be monitored by measuring
the electrical skin conductance.82 Once a drug has traversed
the stratum corneum, the next layer is easier to cross, and
subsequently the drug can reach the capillary vessels to be
absorbed.83 This skin permeabilization method may be use-
ful for avoiding the multiple use of needles, for example, for
delivery of heparin or insulin through the skin.20
Low-Intensity Pulsed Ultrasound 
Low-intensity pulsed ultrasound has therapeutic applica-
tions to accelerate the healing of bone fractures, including
cases of nonunion.21 The characteristics of the pulsed ul-
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trasound, for example, a 1.5-MHz frequency with a 30-
mW/cm2 spatial-average temporal-average intensity, are
in the range of diagnostic ultrasound. The biophysical
mechanisms for the therapeutic action are uncertain for
this application. Therapy involves multiple treatments of
20 minutes each day by applying a large flat transducer to
the site of injury and continuing treatment for periods of
months. Although the process appears to be safe and ef-
fective, the therapy is slow, and its use is predominantly
limited to management of nonhealing fractures. 
Prospective New Methods of Therapeutic
Ultrasound
In this era of ultrasound research, several new means of
applying ultrasound for therapy are undergoing intensive
research and development. The novel methods use low-
frequency, moderate-power ultrasound aided by stabilized
microbubbles for gas body activation or very high-power
pulsed ultrasound with vigorous cavitation.
Direct sonothrombolysis using external, typically low-
frequency ultrasound has been tested for treatment of
thrombotic disease such as stroke.84 This new strategy
shows promise but also has shown a potential for delete-
rious side effects. For example, increased symptomatic
brain hemorrhage was found in a clinical trial for treat-
ment with 300-kHz ultrasound plus tissue plasminogen
activator relative to treatment with tissue plasminogen ac-
tivator alone.85 Recent work suggests that microbubbles
enhance thrombolysis and may be of value in improving
stroke therapy.86
Another potential application in the brain uses trans -
cranial pulsed ultrasound (0.25–0.5 MHz) at relatively low
levels (spatial-peak temporal-average intensity, 26–163
mW/cm2) to produce cortical and hippocampal stimula-
tion in mice.87 Because measured temperature gradients
were less than 0.01°C, nonthermal mechanisms for the
neuronal effects were hypothesized.
Microbubble-based therapeutic strategies are under
study for ultrasound-directed and targeted therapy. In
these strategies, the external ultrasound exposure activates
microbubbles in the circulation, which may also act as drug
carriers, at a desired site of treatment. Microbubble con-
trast agents have also found applications in improving the
therapeutic efficacy of biologically active molecules.88 Sev-
eral possible mechanisms include (1) enhancement of the
concentration of therapeutic biomolecules in the vascular
compartment of the target area, (2) increased therapeu-
tic agent delivery by extravasation through blood vessels,
and (3) potentially enhanced intracellular delivery. Mol-
ecules of the therapeutic agent can be attached to the
outer shells of bubbles, incorporated within the bubble
shells, or loaded in the interior of the microbubbles and
released in the vascular compartment through ultrasound-
induced microbubble disruption.89,90 The extravasation of
a therapeutic agent is achieved through the permeabiliza-
tion of blood vessels with ultrasound and microbubbles,
for example, to cross the blood-brain barrier.91 The ultra-
sound microbubble-based delivery of therapeutic agents
has one main advantage over other techniques using col-
loidal drug carriers such as nanoparticles or liposomes: the
microbubble-based technique may be targeted through the
external control of the ultrasound. This localized approach
may then improve the therapeutic efficacy of drugs, in-
cluding routinely used chemotherapeutic agents such as
paclitaxel. The dose of the agent to normal tissue is low-
ered, with a consequent minimization of unwanted drug
effects away from the treatment site.92 At the cellular level,
ultrasound with microbubbles can be used to transiently
permeabilize cell membranes, allowing transfer of large
molecules into the cells. DNA transfer has been shown in
extensive research on gene therapy applications.93
The cavitation mechanism is also being exploited to
create a new tissue ablation method known as histotripsy.94
In histotripsy (akin to lithotripsy pulses but at a higher fre-
quency), very high-amplitude ultrasound pulses typically
of less than 50 microseconds’ duration at 750 kHz create a
cavitation microbubble cloud to homogenize targeted tis-
sue such as tumors with little heating.95 Longer HIFU
pulses (eg, >3 milliseconds at 2 MHz) of very high inten-
sity can induce rapid heating and also generate cavitation
and boiling with vapor bubbles that expand very rapidly,
thus disrupting tissue.46
Because cavitation is a mechanism secondary to the
ultrasound exposure, the problems of dosimetry and con-
trol are challenging. Determining the energy deposited by
ultrasound with cavitation is difficult under the best of cir-
cumstances.96,97 For cavitating ultrasound, researchers try
to follow 3 rules: (1) understand the medium (including
cavitation nuclei); (2) understand the sound field; and (3)
know when a cavitation effect happens.96 The first rule
refers to the cavitation threshold, whereas the second rule
relates to accurate measurements of the acoustic field. The
third relates to observable cavitation events or secondary
related information that can be monitored. There are var-
ious reliable and scientifically established methods for
quantifying an acoustic field.98–101 Passive detection meth-
ods, measuring broadband acoustic noise from bubble col-
lapse for monitoring cavitation activity, can be deployed,
and research has indicated useful dosimetric parameters
J Ultrasound Med 2012; 31:623–634 629
Miller et al—Therapeutic Ultrasound Applications and Safety Considerations
3104online.qxp:Layout 1  3/16/12  10:46 AM  Page 629
that may be derived for predicting bioeffects.102,103 As new
cavitation-based treatments are developed, new means for
cavitation dosimetry and control will be needed to ensure
optimum patient safety.
General Guidance for Therapeutic 
Ultrasound Safety
Therapeutic ultrasound methods provide a substantial ar-
mamentarium for medical practice. In addition, ultrasound
brings fundamentally favorable safety characteristics to the
clinic. For example, ionizing radiation with its dose accu-
mulation and cancer risk is absent from ultrasound meth-
ods. Low-energy exposures, below the threshold for a
bioeffect, do not accumulate to produce the effect, even if
repeated many times. The ultrasound waves are dispersed
and poorly transmitted in air: no lead gloves, aprons, or
other protective gear are needed for ultrasound diagnosis
or therapy. However, this powerful modality does require
attention to several safety factors to achieve the optimum
risk to benefit ratio.
Operator Safety
The operator of the equipment, for the most part, has lit-
tle risk of harm from the machines and can remain in the
treatment room and safely apply the ultrasound with hand-
held applicators for some applications. However, simple
precautions should be followed for complete operator
safety; for example, do not test therapeutic ultrasound
equipment on oneself or others (as opposed to diagnostic
ultrasound imaging, which can be used on volunteer mod-
els for training purposes under medical supervision).
Patient Safety
Ultrasound therapy machines are, of course, capable of
causing substantial bioeffects; therefore, deliberate caution
must be exercised to minimize injury for each patient. 
Patients should be fully informed of possible risks, as well
as expected benefits. 
Quality Assurance
Ultrasound therapy machines are typically complex and
subject to deterioration or failure. Each machine should be
monitored and tested on a regular basis for safe operation
and verification of appropriate ultrasonic fields to ensure
efficacious treatment.
Accumulating Biological Effects
Although no cumulative dose has been defined for any ul-
trasound therapy, unwanted bioeffects such as scarring
from burns and vascular injury that occur during treatment
can accumulate with repeated treatments, and this possi-
bility should be anticipated. For example, animal studies
show permanent loss of functional renal mass with each
lithotripsy; therefore, recurrent treatments add injury to
already impaired kidneys. 
Risk to Benefit Ratios
The benefits and potential risks associated with different
therapeutic ultrasound methods vary widely and should be
appreciated by the operator. For example, physical ther-
apy ultrasound appears to have a low risk of harm in the
hands of skilled physical therapists, but the expectation of
a therapeutic benefit is also low. Lithotripsy, in contrast,
has the tremendous benefit of noninvasively treating a se-
rious disease, which previously required major surgery, but
it also has a risk of severe hemorrhage and longer-term kid-
ney injury.
Safety Research
The search for new applications of this powerful tool
should be pursued carefully, with thorough testing in 
appropriate animal models to identify possible human 
adverse events before clinical trials begin. Accurate and
precise evaluation of acoustic fields in water and in situ
should follow exposimetry and dosimetry procedures and
numerical modeling previously recognized in the ultra-
sound literature. Means for monitoring heating or sec-
ondary mechanisms, such as acoustic cavitation, should be
in place. Furthermore, to ensure optimum patient benefits
from therapeutic ultrasound, dedicated research should
continually pursue better and safer methods to enhance
present therapies and therapy monitoring.
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